Sign in


Orem, Utah, United States
August 29, 2017

Contact this candidate


Donald C Mix Jr 801-***-****

*** **** *** *****, ****, Utah 84057

Highly skilled scientist with over 20 years of experience who excels at problem solving, innovating methods, and getting results. Flexible and motivated, able to learn complex new skills and procedures. Experienced in surgical and biomedical research, data analysis, analytical chemistry, lab management, experimental design, technical writing including SOPs and formal reports, safety, and quality control.


Extensive in-vivo research and surgical experience Excellent writing and editing skills

Experimental design and problem solving Data analysis and statistical calculations

Quality control and continuous improvement Lab management, training and supervising

Equipment calibration, method validation Regulatory and safety compliance


QA Lab Technician II Sept 2013 – Feb 2017

Sun Products Corp., West Valley City, UT

Conducted analysis of chemical and physical properties of commercial detergents and incoming raw materials for QA approval and manufacturing process control in a cGMP facility.

Wrote lab manual detailing procedures for common tests and operations.

Utilized HPLC, FTIR, pH meters, Karl Fischer and other automatic titrators.

Learned TVC (Total Viable Count) and other microbiology techniques.

Took on increasing responsibilities regarding lab operations including paperwork and SAP review, equipment calibration and maintenance, hazardous waste management, 5S, and safety training.

Developed and validated a new HPLC method for analyzing new ingredients.

Joined the Emergency Response Team and received advanced first aid and rescue training.

Senior Scientist Feb 2005 – May 2013

Aciont Inc., Salt Lake City, UT

Created, designed, and researched new passive and iontophoretic ocular drug delivery systems.

Studied treatments of back-of-the-eye diseases such as uveitis, diabetic retinopathy, and AMD.

Co-investigator and supervisor for all in-vivo experiments; wrote IACUC protocols.

Graded irritation of tissues with indirect ophthalmoscopy and a modified McDonald-Shadduck scale.

Resected, dissected, and processed ocular tissues for drug level analysis.

Performed stability tests on drug formulations and storage conditions.

Analyzed solutions and tissues for drug and metabolite content.

Responsible user for radioactive facilities; managed and maintained company laboratory.

Designed and oversaw in-house studies and GLP studies performed by CROs.

Assisted in the design and engineering of medical devices and packaging.

Participated in formulation and stability studies; assessed sterilization techniques.

Wrote and/or edited formal reports and documents for FDA IND submission.

Donald C Mix Jr 801-***-****

Sr. Research Specialist Aug 1999 – Aug 2004

University of Utah Cardiothoracic Surgery, Salt Lake City, UT

Conducted research on the prevention and reversal of cardiac ischemic contracture and reperfusion injury.

Reduced the rate of in-vivo experiment failure from 20% to 1% by improving procedures and apparatus.

Performed complex cardiac and vascular surgical procedures.

Analyzed tissues to assess levels of ATP and oxidative stress.

Modified assays to better fit needs and available equipment.

Operated and maintained clinical and research equipment including blood chemistry analyzers, UV/vis spectrometers, luminometers, fluorescence detectors, and other general laboratory equipment.

Documented and maintained inventories for DEA and USDA controlled supplies.

Sr. Research Specialist May 1991 – June 1999

University of Utah Dept. of Pharmaceutics, Salt Lake City, UT

Conducted experiments on a wide variety of drug delivery systems.

Studied oral peptide drug delivery systems utilizing enhancers, enzyme inhibitors, site specific release, and/or peptide modifications (prodrugs).

Researched biocompatible, biodegradable, and nonthrombogenic polymers.

Created or modified analytical procedures.

Performed or supervised all aspects of in-vivo research in the group.

Supervised surgical and radioisotope facilities.

Trained students and other researchers in in-vivo, surgical, and other lab techniques.

Managed several concurrent research projects.

Consultant 1997

MacroMed Inc., Salt Lake City, UT

Designed and performed new in-vivo experiments to evaluate and optimize characteristics of novel hydrogel drug delivery systems (ReGel).

Documented, prepared, and reported data.

Designed GLP studies for outside labs.


Bachelor of Science, Chemistry,

University of Utah, Salt Lake City, UT


Radioisotope Responsible User, University of Utah

Project Management, University of Utah

Donald C Mix Jr.

Selected Publications

1.Miller DJ, Li SK, Tuitupou AL, Kochambilli RP, Papangkorn K, Mix DC, Jr., et al. Passive and oxymetazoline-enhanced delivery with a lens device: pharmacokinetics and efficacy studies with rabbits. J Ocul Pharmacol Ther. 2008;24(4):385-91.

2.Stringham JC, Mix DC, Petersen GG, Sorensen, ST. Membrane oxygenation is superior to parabiotic support in blood perfused small animal isolated heart preparations. J Surg Res, Submitted Sept 2004.

3.Stringham JC, Mix DC, Bull DA, Karwande SV, Hawkins JA. BDM does not prevent diastolic dysfunction or reverse ischemic contracture from warm myocardial ischemia. XIX Intl Congress of the Transplantation Society, Miami Fl, USA, Aug 25-30, 2002.

4.Akiyoshi K, Kobayashi A, Shichibe S, Mix D, Baudys M, Kim SW, Sunamoto J. Self assembled nanoparticle of cholesterol bearing pullulan as a carrier of protein drugs: complexation and stabilization of insulin. J Control Rel, 54(3):313-20, 1998.

5.Liu F, Song S-C, Mix D, Baudys M, Kim SW. Glucose induced release of glycosyl polyethylene glycol insulin from its complex with a soluble conjugate of concanavalin A. Bioconjugate Chem 8:664, 1997.

6.Liu F, Baudys M, Mix D, Hinds K, Kim SW. Bioactive polyethylene glycol-insulin conjugates with enhanced stability. Polymer Reprints (ACS) 38:1, 1997.

7.Uchio T, Baudys M, Mix D, Kim SW. Pharmacodynamic and pharmacokinetic study of glycosylated insulin derivative in dog. Proceed Control Rel Bioact Mater 23:883, 1996.

8.Baudys M, Mix D, Kim SW. Stabilization and intestinal absorption of human calcitonin. J Control Rel 39:145, 1996.

9.Baudys M, Uchio T, Mix D, Wilson D, Kim SW. Physical stabilization of insulin by glycosylation. J Pharm Sci 84:28, 1995.

10.Baudys M, Mix D, Kim SW. Stabilization and intestinal absorption of human calcitonin. J Control Rel 39:145, 1996.

11.Baudys M, Uchio T, Song S-C, Mix D, Kim SW. Physical stabilization of insulin through chemical modification: Site-specific glycosylation or PEGylation. Proceed 5th Iketani Conf (Tokyo), Springer, Heidelberg, 1996.

12.Kim SW, Jacobs HA, Bae YH, Gutowska A, Kwon IC, Mix D, Heiber S, Ebert CD. Heparin releasing polymeric devices. Proceed 21st Intl CRS Symp, Nice, France, June 24-30, 1994.

13.Gutowska A, Bae YH, Jacobs H, Mohammed F, Mix D, Feijen J, Kim SW. Heparin release from thermosensitive polymer coatings: In-vivo studies. J Biomed Mater Res 29:811, 1995.

14.Heiber S, Ebert CD, Smith K, Mix D, Kim SW. In-vivo buccal delivery of calcitonin. J Control Rel 28:287, 1994.

15.Baudys M, Mix D, Mack E, Kim SW. Synthesis and characterizations of different glycosylated derivatives of insulin. Proceed Control Rel Bioact Mater, 19:210, 1992.

Contact this candidate